Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients

Wungrak Choi, Sung Eun Park, Hyun Goo Kang, Suk Ho Byeon, Sung Soo Kim, Hyoung Jun Koh, Sungchul Lee, Gong Je Seong, chanyun kim, Min Kim

Research output: Contribution to journalArticle

Abstract

Background/Aims To analyse intraocular pressure (IOP) changes over a period of 1 year after intravitreal dexamethasone (DEX, Ozurdex) implant injection and to compare the results with those of previously published studies that involved non-Asian populations. Methods A retrospective observational study was conducted. A total of 540 eyes of 503 patients who received DEX implant injection and were diagnosed with macular oedema (ME) due to various retinal diseases were examined. IOP was measured prior to injection and at 1 week, 1 month, 2 months, 3 months, 6 months and 12 months after DEX implant injection. IOP elevation was divided into four categories: postinjection IOP of >35 mm Hg, >30 mm Hg and >25 mm Hg, and an IOP elevation of >10 mm Hg, relative to the baseline measurement. Results The mean baseline IOP was 13.45±2.95. The mean IOP gradually increased until 2 months postinjection (IOP=16.85±5.96 mm Hg, p<0.001) and then gradually decreased until 12 months postinjection (IOP=13.80±4.04mm Hg, p=0.16). IOP was >25 mm Hg in 57 eyes (10.6%), >30mm Hg in 29 eyes (5.4%) and >35mm Hg in 9 eyes (1.7%); IOP exhibited >10 mm Hg elevation from the baseline IOP in 61 eyes (11.3%). Overall, the incidence rate of IOP elevation after DEX treatment was 12.6% (68 eyes). Among the 68 eyes (12.6%) with elevated IOP, 60 (11.1%) required treatment: 59 (10.9%) required IOP-lowering medication and 1 (0.2%) ultimately required surgical interventions. Conclusions The incidence of adverse IOP elevation requiring the prolonged use of IOP-lowering medication and surgical intervention after DEX implantation was significantly lower than the incidence reported in previous Western population-based studies. Intravitreal DEX injection may therefore be an effective and relatively safe treatment modality for ME in Asian patients.

Original languageEnglish
Pages (from-to)1380-1387
Number of pages8
JournalBritish Journal of Ophthalmology
Volume103
Issue number10
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Intravitreal Injections
Intraocular Pressure
Dexamethasone
Injections
Incidence
Retinal Diseases
Macular Edema
Population

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Choi, Wungrak ; Park, Sung Eun ; Kang, Hyun Goo ; Byeon, Suk Ho ; Kim, Sung Soo ; Koh, Hyoung Jun ; Lee, Sungchul ; Seong, Gong Je ; kim, chanyun ; Kim, Min. / Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients. In: British Journal of Ophthalmology. 2019 ; Vol. 103, No. 10. pp. 1380-1387.
@article{7130743784094fc2accddedd12371b64,
title = "Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients",
abstract = "Background/Aims To analyse intraocular pressure (IOP) changes over a period of 1 year after intravitreal dexamethasone (DEX, Ozurdex) implant injection and to compare the results with those of previously published studies that involved non-Asian populations. Methods A retrospective observational study was conducted. A total of 540 eyes of 503 patients who received DEX implant injection and were diagnosed with macular oedema (ME) due to various retinal diseases were examined. IOP was measured prior to injection and at 1 week, 1 month, 2 months, 3 months, 6 months and 12 months after DEX implant injection. IOP elevation was divided into four categories: postinjection IOP of >35 mm Hg, >30 mm Hg and >25 mm Hg, and an IOP elevation of >10 mm Hg, relative to the baseline measurement. Results The mean baseline IOP was 13.45±2.95. The mean IOP gradually increased until 2 months postinjection (IOP=16.85±5.96 mm Hg, p<0.001) and then gradually decreased until 12 months postinjection (IOP=13.80±4.04mm Hg, p=0.16). IOP was >25 mm Hg in 57 eyes (10.6{\%}), >30mm Hg in 29 eyes (5.4{\%}) and >35mm Hg in 9 eyes (1.7{\%}); IOP exhibited >10 mm Hg elevation from the baseline IOP in 61 eyes (11.3{\%}). Overall, the incidence rate of IOP elevation after DEX treatment was 12.6{\%} (68 eyes). Among the 68 eyes (12.6{\%}) with elevated IOP, 60 (11.1{\%}) required treatment: 59 (10.9{\%}) required IOP-lowering medication and 1 (0.2{\%}) ultimately required surgical interventions. Conclusions The incidence of adverse IOP elevation requiring the prolonged use of IOP-lowering medication and surgical intervention after DEX implantation was significantly lower than the incidence reported in previous Western population-based studies. Intravitreal DEX injection may therefore be an effective and relatively safe treatment modality for ME in Asian patients.",
author = "Wungrak Choi and Park, {Sung Eun} and Kang, {Hyun Goo} and Byeon, {Suk Ho} and Kim, {Sung Soo} and Koh, {Hyoung Jun} and Sungchul Lee and Seong, {Gong Je} and chanyun kim and Min Kim",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/bjophthalmol-2018-312958",
language = "English",
volume = "103",
pages = "1380--1387",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "10",

}

Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients. / Choi, Wungrak; Park, Sung Eun; Kang, Hyun Goo; Byeon, Suk Ho; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Sungchul; Seong, Gong Je; kim, chanyun; Kim, Min.

In: British Journal of Ophthalmology, Vol. 103, No. 10, 01.01.2019, p. 1380-1387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients

AU - Choi, Wungrak

AU - Park, Sung Eun

AU - Kang, Hyun Goo

AU - Byeon, Suk Ho

AU - Kim, Sung Soo

AU - Koh, Hyoung Jun

AU - Lee, Sungchul

AU - Seong, Gong Je

AU - kim, chanyun

AU - Kim, Min

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aims To analyse intraocular pressure (IOP) changes over a period of 1 year after intravitreal dexamethasone (DEX, Ozurdex) implant injection and to compare the results with those of previously published studies that involved non-Asian populations. Methods A retrospective observational study was conducted. A total of 540 eyes of 503 patients who received DEX implant injection and were diagnosed with macular oedema (ME) due to various retinal diseases were examined. IOP was measured prior to injection and at 1 week, 1 month, 2 months, 3 months, 6 months and 12 months after DEX implant injection. IOP elevation was divided into four categories: postinjection IOP of >35 mm Hg, >30 mm Hg and >25 mm Hg, and an IOP elevation of >10 mm Hg, relative to the baseline measurement. Results The mean baseline IOP was 13.45±2.95. The mean IOP gradually increased until 2 months postinjection (IOP=16.85±5.96 mm Hg, p<0.001) and then gradually decreased until 12 months postinjection (IOP=13.80±4.04mm Hg, p=0.16). IOP was >25 mm Hg in 57 eyes (10.6%), >30mm Hg in 29 eyes (5.4%) and >35mm Hg in 9 eyes (1.7%); IOP exhibited >10 mm Hg elevation from the baseline IOP in 61 eyes (11.3%). Overall, the incidence rate of IOP elevation after DEX treatment was 12.6% (68 eyes). Among the 68 eyes (12.6%) with elevated IOP, 60 (11.1%) required treatment: 59 (10.9%) required IOP-lowering medication and 1 (0.2%) ultimately required surgical interventions. Conclusions The incidence of adverse IOP elevation requiring the prolonged use of IOP-lowering medication and surgical intervention after DEX implantation was significantly lower than the incidence reported in previous Western population-based studies. Intravitreal DEX injection may therefore be an effective and relatively safe treatment modality for ME in Asian patients.

AB - Background/Aims To analyse intraocular pressure (IOP) changes over a period of 1 year after intravitreal dexamethasone (DEX, Ozurdex) implant injection and to compare the results with those of previously published studies that involved non-Asian populations. Methods A retrospective observational study was conducted. A total of 540 eyes of 503 patients who received DEX implant injection and were diagnosed with macular oedema (ME) due to various retinal diseases were examined. IOP was measured prior to injection and at 1 week, 1 month, 2 months, 3 months, 6 months and 12 months after DEX implant injection. IOP elevation was divided into four categories: postinjection IOP of >35 mm Hg, >30 mm Hg and >25 mm Hg, and an IOP elevation of >10 mm Hg, relative to the baseline measurement. Results The mean baseline IOP was 13.45±2.95. The mean IOP gradually increased until 2 months postinjection (IOP=16.85±5.96 mm Hg, p<0.001) and then gradually decreased until 12 months postinjection (IOP=13.80±4.04mm Hg, p=0.16). IOP was >25 mm Hg in 57 eyes (10.6%), >30mm Hg in 29 eyes (5.4%) and >35mm Hg in 9 eyes (1.7%); IOP exhibited >10 mm Hg elevation from the baseline IOP in 61 eyes (11.3%). Overall, the incidence rate of IOP elevation after DEX treatment was 12.6% (68 eyes). Among the 68 eyes (12.6%) with elevated IOP, 60 (11.1%) required treatment: 59 (10.9%) required IOP-lowering medication and 1 (0.2%) ultimately required surgical interventions. Conclusions The incidence of adverse IOP elevation requiring the prolonged use of IOP-lowering medication and surgical intervention after DEX implantation was significantly lower than the incidence reported in previous Western population-based studies. Intravitreal DEX injection may therefore be an effective and relatively safe treatment modality for ME in Asian patients.

UR - http://www.scopus.com/inward/record.url?scp=85058319692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058319692&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2018-312958

DO - 10.1136/bjophthalmol-2018-312958

M3 - Article

AN - SCOPUS:85058319692

VL - 103

SP - 1380

EP - 1387

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 10

ER -